An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

Andrzej P. Kudelka, Rodger J. Winn, Creighton L. Edwards, Gabrielle Downey, Harvey Greenberg, SR Dakhil, Ralph S. Freedman, Salvatore Lococo, Jay N. Umbreit, James E. Delmore,

Anti-Cancer Drugs · 1997 · 54 citations · 0 references

Concepts

Abstract

UNLABELLED: Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. IN CONCLUSION: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.